A Phase 4 interventional study of Lifitegrast 5% Ophthalmic Solution and Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution in Dry Eye Syndromes, sponsored by Eye Surgeons of Indiana. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Eye Surgeons of Indiana · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 16th largest by enrollment, is one of 5 that started in 2020, is one of 12 in phase 4, and was the 9th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2020.
This study's enrollment of 5 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 36 across the 16 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 16 have an industry lead sponsor. The 10 most frequent:
Eye Surgeons of Indiana is the lead sponsor of 2 studies on the registry; none are open to participants now.
Eye Surgeons of Indiana has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.
This prospective study will use a fellow-eye design for 20 participants, 40 eyes. All eyes will receive bilateral Xiidra. The most symptomatic eye will be selected to receive DEXTENZA® insertion on the day Xiidra is prescribed (study eye), while the other eye will be assigned to receive sham punctum dilation (control eye). If there is no obvious symptomatic difference, the right eye will receive the intracanalicular insert. The study group will consist of 20 eyes receiving DEXTENZA® insertion. The control group will consist of 20 eyes receiving sham punctum dilation. Thus, for every eye in the study group, there will be a paired eye with similar baseline characteristics in the control group sourced from the same participant. This fellow-eye design allows for greater control of potential confounders tied to participants' systemic and ocular health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient's study eye must meet the following criteria to be eligible for inclusion in the study:
Exclusion Criteria:
A patient who meets any of the following criteria will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with dry eye disease Xiidra only
Drug: Lifitegrast 5% Ophthalmic Solution
Patients with dry eye disease Xiidra + Dextenza
Drug: Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
To reduce signs and symptoms of dry eye disease
Also known as: Xiidra
Drug page: DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
Also known as: Dextenza, Xiidra
Mean Change in Ocular Surface Staining
As measured by sodium fluorescein and lissamine green
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Patient Preference for Therapy
As measured by COMTOL Survey
Time frame: Assessed at Week 12 Visit
Mean Change in MMP-9
As measure by InflammaDry
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Mean Change in Conjunctival Injection
As measured on a scale of 0-4 and graded by the physician
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Change From Baseline in Meibomian Gland Scores (Expressibility and Quality)
As measured on a grading scale 1 to 4 and graded by the physician
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Mean Change in Tear Break-up Time (TBUT)
As measured by TBUT testing
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Mean Change in Tear Osmolarity
As measured by Tear Lab
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Mean Change in DEQ-5
As measured by the DEQ-5 Questionnaire
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
Mean Change in Best-corrected Visual Acuity (BCVA)
As measure by ETDRS
Time frame: Assessed at Baseline, Week 1, Week 2, Week 4 and Week 12 Visit
The study was terminated due to inability to recruit. Five participants provided informed consent and were enrolled; however, no participants were assigned to an Arm/Group or received study intervention.
| Milestone | Xiidra Only Group | Xiidra + Dextenza Group |
|---|---|---|
| Started | 0 | 0 |
| Completed | 0 | 0 |
| Not completed | 0 | 0 |
As measured by sodium fluorescein and lissamine green
No measurements were reported for this outcome.
As measured by COMTOL Survey
No measurements were reported for this outcome.
As measure by InflammaDry
No measurements were reported for this outcome.
As measured on a scale of 0-4 and graded by the physician
No measurements were reported for this outcome.
As measured on a grading scale 1 to 4 and graded by the physician
No measurements were reported for this outcome.
As measured by TBUT testing
No measurements were reported for this outcome.
As measured by Tear Lab
No measurements were reported for this outcome.
As measured by the DEQ-5 Questionnaire
No measurements were reported for this outcome.
As measure by ETDRS
No measurements were reported for this outcome.
Collected over Not applicable. No participants started the trial or received study intervention prior to study termination on April 11, 2022; therefore, adverse events were not monitored or assessed.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Xiidra + Dextenza Group | — | — | — |
| Xiidra Only Group | — | — | — |
No baseline characteristics were collected because no participants started the trial, were assigned to an Arm/Group, or received study intervention prior to study termination. Therefore, the overall number of baseline participants is 0.
| Age, Categorical | Xiidra Only Group | Xiidra + Dextenza Group | Total |
|---|---|---|---|
| <=18 years | — | — | — |
| Between 18 and 65 years | — | — | — |
| >=65 years | — | — | — |
| Age, Continuous | Xiidra Only Group | Xiidra + Dextenza Group | Total |
|---|
| Sex: Female, Male | Xiidra Only Group | Xiidra + Dextenza Group | Total |
|---|---|---|---|
| Female | — | — | — |
| Male | — | — | — |
| Race (NIH/OMB) | Xiidra Only Group | Xiidra + Dextenza Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | — | — | — |
| Asian | — | — | — |
| Native Hawaiian or Other Pacific Islander | — | — | — |
| Black or African American | — | — | — |
| White | — | — | — |
| More than one race | — | — | — |
| Unknown or Not Reported | — | — | — |
| Region of Enrollment(participants) | Xiidra Only Group | Xiidra + Dextenza Group | Total |
|---|
Ran from Aug 2020 to primary completion in Apr 2022, 20 months.
Results were first posted in Oct 2026, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Eye Surgeons of Indiana